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Summary The proliferation rate (as assessed by Ki67 expression) and expression of oestrogen-regulated progesterone receptor (PR) was
studied in normal post-menopausal breast epithelium. Normal breast epithelium from patients receiving hormone replacement therapy (HRT)
at the time of surgery containing either oestrogen alone (E2) or oestrogen and progesterone combined activities (E2 + P) was also studied, as
HRT has been linked to an increased breast cancer risk. Samples of breast tissue. containing normal epithelium. from 185 patients
undergoing surgery for benign or malignant disease were immunocytochemically stained for PR and Ki67. The percentage of labelled cells
was expressed as the labelling index (LI). The median Ki67 Li in normal post-menopausal breast epithelium was 0.19 and median PR LI was
4.75, and both were unaffected by patient age, duration of menopause or if the tissue sample originated from a breast with benign or
malignant disease. Proliferation did not alter significantly in patients taking HRT (P = 0.61); however, PR expression was up-regulated in both
E2 and E2 + P users (P = 0.01). The dose and duration of HRT had no effect on either parameter. A possible attenuation of sensitivity to
oestradiol-induced proliferation but not to PR expression occurs in the post-menopausal breast.
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Increased normal epithelial cell proliferation is linked to the dexel-
opment of cancer in human tissue (Preston-Martin et al. 1990).
Most studies of normal breast epithelium hax-e been confined to
premenopausal tissue. %N-hich has been shown to be hormone
dependent. responding to changes in serum steroid hormone levels
through the menstrual cN-cle (Mever. 1977: Anderson et al. 1982:
Potten et al. 1988) with 17-p-oestradiol acting as one of the most
important epithelial cell mitogens in the breast. Thus. the risk of
breast cancer is reduced in w-omen who have a reduced life-time
exposure to oestradiol (Key and Pike. 1988). presumably- because
of a reduction in breast proliferation. The role of progesterone
upon breast proliferation remains unclear. as an inhibitory function
has been described (Chang et al. 1995). although other studies
hax-e failed to find anv effect (Laidlax- et al. 1995).
Although breast cancer incidence is at its hiahest in post-
menopausal women. little information is axailable regarding the
proliferation rate of normal post-menopausal breast epithelium.
Those studies undertaken has-e been on small numbers of patients
(Mever and Connor. 1982: Jacquemier et al. 1990: Walker et al.
199 ). The axerage age of menopause in dexveloped countries is
betueen 50 and 51 vears (McKinlav et al. 1992). Although oestra-
diol ceases to be the principal oestrogen in these women. non-
ox arian svnthesis of oestradiol continues as a result of peripheral
conversion of androgens by the aromatase enz%-me (Soules and
Bremner. 1982: Yates et al. 1996). Oestradiol up-regulates proges-
Received 12 November 1997
Revised 19 February 1998
Accepted 3 March 1998
Correspondence to: DF Hargreaves
terone receptor (PR) expression in breast epithelium (Horx-itz and
McGuire. 1978: Williams et al. 1991) and the little information
available for post-menopausal w-omen indicates that PR expres-
sion is maintained. although at lox er lexels than in premenopausal
breast (Jacquemier et al. 1990: Walker et al. 1991).
Reduced circulatinc oestradiol is responsible for manv of the
unpleasant symptoms of the menopause. including hot flushes.
sex ere perspiration and genital tract atrophy (Greendale and Judd.
1993). More serious health risks include an increased incidence of
cardioxascular disease (Sullixvan and Foxlkes. 1996) and osteo-
porosis (Greendale and Judd. 1993). Howexer. the menopause
appears to confer some protection upon breast cancer risk. Breast
cancer incidence in >-omen increases 'ith age. but the rate of
increase slowxs sharply oxer the age of 50 (Key and Pike. 1988).
Additionally. in A-omen surgically induced to the menopausal
state. future breast cancer risk is reduced by up to 60%s
(Trichopoulos et al. 1972). Hormone replacement therapy (HRT).
increasingly prescribed to treat menopausal symptoms (Moorhead
et al. 1997). contains either oestrogen (mainly oestradiol) alone
(E,) or oestrogen and progesterone actixities combined (E, + Pg).
Concern has been raised that prolonging exposure of the post-
menopausal breast to oestradiol (i.e. HRT) could promote breast
cancer (Howxell et al. 1995). Indeed. data suggest that prolonged
use of HRT increases breast cancer incidence (Bergkvist et al.
1989: Colditz et al. 1995: Beral et al. 1997). An animal model.
used to predict the effects of HRT upon human post-menopausal
breast. has demonstrated that primate mammarx gland prolifera-
tion is sigmficantlv increased in response to HRT (Cline et al.
1996). Hoxexver. the effect of HRT upon normal human breast
tissue remains unknowxn. The aim of the present study wxas to
determine the range of epithelial proliferation in normal breast
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epithelium from a large group of post-menopausal wxomen and
hox- this wxas effected bv HRT. We also studied progesterone
receptor expression as a marker of oestrogen responsiveness.
MATERIALS AND METHODS
Patients
A retrospective studx of 185 women w-ho had undergone breast
biopsy or surgerx at the Unixersity Hospital of South Manchester
for malignant (n = 124) or benian breast disease (n = 61) was
carred out. Menopausal status. length of menopause. details of
HRT. familx history of breast disease. pathology of the tissue
sample and parity at time of surgery A-ere obtained from the
clinical notes and from the patient's GP. Women x-ere considered
menopausal if it A-as documented that their menstrual cycles had
ceased for at least 1 year. or if they w-ere oxver 50 and had been
hN-sterectomized (Harding et al. 1996). When this information A-as
unknown. we included patients ifthey were oxer60 Nears ofage or
if their GP confirmed their menopausal status. As the axeragre age
of menopause is between 50 and 51 years in women from dexel-
oped countries (McKinlay et al. 1992) A-e also included 12 A-omen
aaed between 50 and 59. although there x as no record oftheir last
menstrual period available from either theirhospital records orGP.
Women Awere placed into the HRT group if they had taken HRT at
the time of surgerv (n = 71 ) or x-ithin the month before surgery
(n = 3 . Thirty-five patients wxere prescribed oestrogen-only
therapy and 39 oestrogen and progestin actixity combined. For
patients prescribed oestrogen with cyclical progesterone. informa-
tion was unavailable regarding x hich cycle oftreatment they wxere
taking at the time ofsurgery. Patients x ere not included ifthex had
receixved radiotherapy or tamoxifen therapy before surgery.
Tissue samples
Archixal samples of breast tissue for each patient x-ere obtained
from the pathology departments of the Christie Hospital and
Unixersity Hospital of South Manchester. These samples had been
routinely fixed in formal saline at the time of surgery and
embedded in paraffin xxax. Sections of tissue from each patient
xere stained with haematoxvhn and eosin (H & E) before exami-
nation by a consultant patholocist. who confirmed the presence of
histologzically normal breast epithelium.
Ki67 and PR immunohistochemistry
W7ax sections (3-5 gim thick) of tissue from each patient were cut.
mounted on APES (3-aminopropyltriethoxvsilane. Sigma)-coated
slides. dexxaxed and hNydrated before immunohistochemical
staining for the Ki67 antioen. Further sections wxere cut from
blocks in wxhich sufficient normal epithelium remained and these
x-ere immunohistochemically- assayed for PR.
Ki67 labelling
Antioen retriexal xxas achieved bx a microwaxe method (Bromlev
et al. 1996). and endogenous peroxidase activity blocked by incu-
bation in 0.3%' (x/x) hydrogen peroxide in phosphate-buffered
saline (PBS) for 15 min. Slides were rinsed in PBS and tissue
blocked with 0.5%7 casein in PBS for 1 h at room temperature (RT)
followed by incubation xxith rabbit affinity purified anti-Ki67
poiyclonal antibody (Dako) at 1:100 in PBS for 30min (RT).
Serial sections % ere incubated in rabbit immunoglobulin (l1g)
(Dako negative control) diluted to the same protein concentration
as the primary antibody. to act as a negative control. Slides were
rinsed in PBS and tissue incubated with biotinvlated swine F(ab'),
anti-rabbit lg (Dako) at 1:4(00 in PBS for 30 min (RT) followed by
further rinsing in PBS. Tissue %vas incubated in streptavidin ABC-
HRP (Dako) for 30 min. rinsed in PBS and finallv visualized in
0.03% (v/x hydrogen peroxide 0.44 mg ml-' 3.3. diaminobenzi-
dine 4-HCL (DAB. Sigma) in PBS for 6 min. followed by further
rinsing. Sections were counterstained in Gill's haematoxylin. A
positive control slide of breast tissue know-n to be Ki67-positive
was included in each immunohistochemical staining assay.
PR labelling
Tissue sections were cut. dew-axed and non-specific activity
blocked as above. but the microwave antigen retrieval step was
omitted. Sections were labelled for PR using serum from the PgR-
ICA kit (Abbott Diagnostics). Tissue was incubated with the
primary rat monoclonal antibody diluted 1:4 with PBS overnight
(RT). Serial sections were incubated with negative control serum
at the same dilution. Sections were rinsed in PBS and incubated
with biotinylated rabbit anti-rat Ig (Dako) diluted 1:100 in PBS for
30 min (RT) followed by further rinsing in PBS. Tissue was incu-
bated in streptavidin ABC-HRP (Dako) for 30 min. rinsed in PBS
and finallv xisualized in DAB from the Abbot kit. Sections were
rinsed in PBS and counterstained in haematoxylin. A PgR-ICA kit
positive control slide (Abbott Diagnostics) was included in each
immunohistochemical staining assay.
Scoring
Only epithelium of the terminal duct lobular unit Awas examined.
This is the functional unit of the breast and the area in which most
malignant lesions are thought to develop (Wellings et al. 1975).
This also allows comparison with many of the studies of
premenopausal breast. which considered lobular epithelium only
(Anderson et al. 1982: Potten et al. 1988: Williams et al. 1991). No
attempt w-as made to distinguish between myoepithelial and
luminal epithelial cells. Ki67- and PR-labelled cells were scored
either as positixe or negratixe. Cells were considered positive if
DAB precipitate was clearly present over the nucleus. A minimum
of 900 cells was scored from sexeral randomly selected areas of
the tissue sample and the percentage of labelled cells expressed as
the labelling index.
Table 1 Summary of Ki67 LIl° and PR LI°o in normal breast tissue from
control patents and pabents taking HRT
Ki67 LU PR Ll%
Treatment group Treatment group
Control E2 E2+P Control E2 E2+P
n 111 35 39 100 31 36
Interquartile
range 0.09-0.43 0.1-0.44 0.09-0.87 1.32-8.074.89-17.40 1.06-13.05
Median 0.19 0.22 0.25 4.75 10.21 6.68
Range 0-3.66 0-1.44 0-2.80 0-38.91 0.19-40.16 0-44.36
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Spearman's non-parametric correlation (rho) was used to look for
associations and the Mann-Whitnex (M-W) test w-as used to look
for differences between dichotomous groups. 'Where more than
two groups were compared. the Kruskal-Wallis (K-W) non-
parametric one-way ANOVA A-as used.
RESULTS
The mean age of patients in the control group was 57.4 (s.d. ± 5.1.
range 49-68) years and 55.1 (s.d. ± 4.2. range 49-66) years in
those taking, HRT. Information recardingy menopause length was
known for 140 (76'%) patients. Length of time since the
menopause at time of surgery ranged from 3 to 300 months
[median = 60. interquartile (IQ) ranae = 27-32 months] in the
control group and 5-324 months (median = 65. IQ range = 36-96
months) in the HRT group. Data concerning duration of HRT use
A-ere known for 72 (97%7c) of the patients in the treatment group
and ranged from I to 264 months (median = 36. IQ range = 12-66)
months. Information regarding HRT dose was obtained for all
treated patients. Daily oestradiol. oestradiol valerate or conjugated
oestrogen doses. for patients taking, either oestrogen alone or
oestrogen and progestin combined therapy. ranged from 10 to
2000 jga. Parity status was known for 171 (92%) patients and 151
of these w-omen had been through a full-term pregnancy.
A summary of the ranges and median Ki67 labelling index (LI)
and PR LI from both treatment groups is presented in Table 1. Ki67
LI w-as measured in tissue from all the control patients (Figure 1A)
and found to be unrelated to patient age (within the range of49-68
years) (n = Il1. rho = 0.002. P = 0.49). There was an insignificant
trend tow-ards a decrease in Ki67 LI with an increase in length of
time since the menopause (n = 86. rho = - 0.173. P = 0.06). Tissue
samples from 100 (90%c) control patients A-ere assayed for PR
expression (Figure 1B). Expression was unaffected by patient age
(n = 100. rho = 0.07. P = 0.25) and the length of time since
menopause (n = 78. rho = 0.112. P = 0.16). In control patients
normal breast tissue taken adjacent to a benign lesion showed no
difference compared with tissue taken adjacent to a malignant
lesion in either the Ki67 LI (benign lesions. n = 31. median = 0.175.
IQ range = 0.0-0.49: malignant lesions. n = 80. median = 0.19. IQ
range = 0.10-0.41 ) or PR LI (benign lesions. n = 28. median = 4.6.
IQ range = 0.71-8.02: malignant lesion. n = 72. median = 4.75. IQ
range = 1.45-8.77) (M-W' P = 0.4). Ki67 and PR LI were signifi-
cantly correlated (n = 100. rho = 0.294. P = 0.001).
Tissue samples from all patients receiving, HRT were assayed
for Ki67 expression. There was no significant difference betx-een
Ki67 LI in patients receiving E or E, + P HRT and the control
group (K-WA P = 0.61 ) (Figure 1A). PR LIs in patients takin, both
types of HRT were significantly higher than the control group
(K-W P = 0.01) (Figure 1B). but did not differ significantly
betw een the two types of HRT user. HRT dose and the duration of
use did not correlate with any ofthe parameters measured.
DISCUSSION
In comparison with our studies of Ki67 expression in normal
premenopausal breast (McNMichael-Phillips et al. 1996). prolifera-
tion in the post-menopausal breast is markedly reduced. We previ-
ously demonstrated that Ki67 labellin, averaged from 2.16%7c in
the follicular phase to 12.60%/c in the luteal phase of the menstrual
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by line. 'Statstcally significantty different to control group (K-W P = 0.01)
cy cle using, the same staining methods. Smaller studies have also
shown a reduction in breast proliferation in post-menopausal
women (Meyer and Connor. 1982: Walker et al. 1991). Oestradiol
is one of the most potent stimulators of epithelial proliferation in
the premenopausal breast and the severely reduced oestradiol
levels present after the menopause presumably result in a lack of
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stimulation and the lowered proliferation rates that we have
demonstrated. It is well documented that age also exerts a signifi-
cant negative effect upon proliferation in premenopausal (Meyer
1977: Anderson et al. 1982: Potten et al. 1988) and post-
menopausal (Mever and Connor. 1982) breast epithelium.
Howvever. in this laruer studv. we were unable to find anv influence
of age upon any of the parameters measured in post-menopausal
breast. Although the mechanism of the age effect remains
unknown. our findings imply that the reduction in proliferation
with increasing age may reach a plateau during the climacteric
stage of menopause or at its commencement. There was a slight
trend towards a reduction in proliferation with an increase in the
number of months since the menopause: however. this remained
insianificant.
We found that PR expression is maintained in the post-
menopausal breast. although at a low-er level than that in
premenopausal women. in whom PR LI averages from 12.60%e in
the follicular phase to 16.45%- in the luteal phase of the menstrual
cycle (McMichael-Phillips et al. 1996). Oestradiol up-regulates
PR expression in the epithelial elements of normal human breast
xenografts (Laidlaw et al. 1995). Recent evidence sugaests that PR
expression is sensitive to low levels ofoestradiol and higher levels
are required to generate a proliferative response (Clarke et al.
1997). This could explain the reasonably high expression of PR in
post-menopausal breast epithelium compared with the lowered
rate ofproliferation.
The use of exogenous hormones (e.g. the oral contraceptive)
increases epithelial proliferation in normal premenopausal breast
(W-Illiams et al. 1991: Chancg et al. 1995 . Additionally. HRT
increases proliferation of the endometrium. which is also an
oestrogen-responsive tissue (Whitehead et al. 1981). The use of
HRT (E, or E,+ P) by our patients did not increase their breast
epithelial proliferation index. suggesting that. postmenopausally. the
breast may be less sensitive to oestrocen stimulation. A further
explanation is that HRT failed to raise serum oestradiol to levels
sufficiently high to stimulate proliferation. although levels were
sufficient to treat menopausal symptoms. Serum samples from
patients in this study were unavailable. but previous studies with a
range of HRT preparations have been shown to raise serum oestra-
diol levels to those found in premenopausal women during the
follicular phase of the menstrual cycle (Lind et al. 1979: Whittaker
et al. 1980). and follicular phase oestradiol doses have been shown
to increase siognificantly proliferation of normal premenopausal
breast xenografts (Laidlaw et al. 1995). Although some patients in
our study were receiving quite large levels of oestrogen. varying
HRT doses did not relate to proliferation. A decline in
premenopausal breast epithelial proliferation occurs with age.
although the evidence that serum oestradiol levels also decline is
lacking (Meyer 1977: Anderson et al. 1982: Potten et al. 1988).
sugestin2 that sensitivity ofthe breast to oestradiol attenuates with
ace. This mav result in the failure of low doses of oestrocen. in the
form ofHRT. to elicit aproliferative response. However. w-e did find
that PR expression was higher in both types of HRT user compared
with control subjects and there is evidence tosuagest that the oestra-
diol dose required to up-regulate PR expression is lower than that
required to induce proliferation within the human breast (Clark-e et
al. 1997). Ourfindings differ to those presented by Cline et al ( 1996)
in which mammary proliferation was significantlv increased in
post-menopausal' macaque monkeys administered HRT. However.
in that study. the reproductive history ofeach monkey was unknown
and an early- menopause was artificially induced. Ageing of the
breast may have a role in attenuating oestrogen responsiveness and
could account for the difference in response.
Endogenous and exogenous oestrogens are thought to
contribute to breast cancer risk. primarily by increasing breast cell
mitogenesis (Howell. 1989: Pike et al. 1993). Lona-term HRT use
has been shown in multiple studies to be associated with increased
breast cancer risk (Brinton et al. 1981: Colditz et al. 1995: Beral et
al. 1997) and it is thought this may be due to a sustained increase
in breast proliferation over several years. Althouah duration of
HRT use was considered in our analysis. we w-ould not expect to
pick up this effect using this type of study. We have provided
evidence that HRT is oestrogenic upon post-menopausal breast
tissue as PR expression is raised. We were unable to detect any
significant increase in proliferation. but it is possible that patient
numbers were insufficient to detect very small increases in normal
breast proliferation. Some types ofbenign breast lesions are asso-
ciated with an increased risk of subsequently developing cancer
(McDivitt et al. 1992) and non-malignant lesions have been shown
to express the oestrogen receptor (Jaquemier et al. 1982). This
suggests that benign lesions could respond to exogenous oestrogen
and HRT may increase breast cancer risk by promoting the devel-
opment of these premalignant lesions. initiated earlier in the
patient s life. In addition. anti-oestrogens are commonly used in
the treatment of breast cancer and have been shown to decrease
tumour cell proliferation in *isvo (Clarke et al. 1993). suggesting
that HRT could accelerate the growth and subsequent detection of
early. preinvasive malignant lesions.
ACKNOWLEDGEMENTS
We thank Shaheena Sarwar. Lesley Shaw. Vicki Harvev. Ashu
Gandhi and the histology department of the PICR for technical
assistance. We are also grateful to the Cancer Research Campaign
for the use of their facilities and to the Ministr- of A'riculture
Fisheries and Food for providing the salanr for DFH.
REFERENCES
Anderson TI. Fermuson DIP and Raab GM 1982 Cell turnover in the -restine
human breast: influence ofparit. contraceptive pill. age and lateralit.
BrJ Cancer 46: 376-382
Beral \V Bull D. Doll R. Ke\ T. Peto R and Reeves G (1 997 Breast cancer and
hormone replacerent therapy: collaborati-e reanalx sis of data from 51
epidemioloeical studies of 52 705 A-omen with breast cancer and 108 411
v omen w-ithout breast cancer. Lancer 350: 1047-1059
Berkvist L. Adami H. Persson I. Hoover R and Schairer C 1989 T-he risk of breast
canrcer after estrogen and estrogen-progestin replacement. NEng.1 JMed 321:
293-297
Brinton LA. Hoover RN. Szkluo MI and Fraumeni JF 198 1 M Menopausal estrogen use
and risk of breast cancer. Cancer47 '517-'5
Bromlev NM. Res% D. Becciolini A. Balxi NI. Chadwick C. Hewitt D. Li YQ and
Potten CS 1996 A comparison ofproliferation markers Brd UrdL 7Ki-.
PCNA) determined at each cell position in the cr -pus of normal human colonic
mucosa EurJ Hisrochem 40: 89-100
Chang K. Lee TYT. Linares-Cruz G. Fournier S and de Lienieres B (1995;)
Influences of percutaneous administration of estradiol and progesterone in
human breast epithelial cell cxcle in vi,o. Ferrilirv Sterihr-v 63: 785-791
Clarke RB. LaidlavI U. Jones LI. HoAell A and Anderson E (1993) Effect of
tamoxifen on Ki67 labelline index in human breast tumours and its
relationshiop to oestrogen andprogesterone receptor status. Br J Cancer67:
606-611
Clarke RB. HoAell A and Anderson E (1997 Estrozen sensitivitv of normal human
breast tissue in v-iv-o and implanted into ath rmic nude mice: analysis of the
relationship betu-een estrogen-induced proliferation and progesterone receptor
expression. Breast Cancer Res Trear 45>: 121-133R
British Joumal ofCancer (1998) 78(7). 945-949 C Cancer Research Campaign 1998Post-menopausal breastproliferation, PR status andHRT 949
Cline IM. Soderqist G. Schoultz E. Skoog L and von Schoultz B (1996) Effects of
hormone replacement therapy on the mammary gland ofsurgically
postmenopausal cynomolgus macaques. Am J Obstet Gynecol 174: 93-100
Colditz GA. Hankinson SE. Hunter DJ. Wllett WC. Manson JE. Stampfer MJ.
Hennekens C. Rosner B and Speizer FE (1995) The use ofestrogens and
progestins and the risk ofbreast cancer in p o sal women. N EnglJ
Med332: 1589-1593
Greendale GA and Judd HL (1993) The menopause: health implications and clinical
management. JAm Geriatr Soc 41: 426-436
Harding C. Knox W. Faragher EB. Baildam A and Bundred NJ (1996) Hormone
replacement therapy and tumourgrade in breast cancer prospectve study in
screening unit. BrMedJ312: 1646-1647
Horsuitz KB and McGuire WL (1978) Estrogen control ofprogesterone receptor in
human breast cancer. JBiol Chem 253: 2223-2218
Howell A ( 1989) Clinical evidence for the involvement ofoestrogen in the
development and progression ofbreast cancer. Proc R Soc Edin 95B: 49-57
Howell A. Baildam A. Bundred N. Evans G and Anderson E (1995) Should I take
HRT. doctor" Hormone replacement therapy in women at increased risk of
breast cancer and in survivors ofthe disease. JBrMenopause Soc October:
9-17
Jacquemier JD. Rolland PH. Vague D. Lietaud R. Spitalier JM and Martin PM
(1982) Relationships between steroid receptor and epithelial cell proliferation
in benign fibrocystic disease ofthe breast- Cancer49 2534-2536
Jacquemier JD. Hassoun J. Torrente M and Martin P (1990) Distribution ofestrogen
and progesterone receptors in healthy tissue adjacent to breast lesions at various
stages - immunohistochemical study of 107 cases. Breast Cancer Res Treat 15:
109-117
Kev TJA and Pike MC (1988) The roe ofoestoens and progestagens in the
epidemiology and prevention ofbreast cancer. EurJ Cancer24: 29-43
Laidlaw I. Anderson E. Clarke R. Potten CS and Howell A ( 1995) The proliferation
ofnormal human breast tissue implanted into ahymiic nude mice is stimulated
by oesten but not progesterone. Endocrinology 136: 164-171
Lind T. Cameron EC. Hunter WM. Leon C. Moran PF. Oxley A. Gerrard J and Lind
UCG (1979) A prospective. controlled trial of six forms ofhormone
replacement therapy given to postmenopausal women. BrJ Obstet Gvnecol
86,S3: 1-29
McDivitt RW. Stevens JA. Lee NC. Wingo PA. Rubin GL and Gersell D (1992)
Histologic types ofbenign breast disease and the nrsk for breast cancer. Cancer
69:1408-1414
McKinlav SM. Brambilla DJ. PosnerJG (1992) The nonnal menopause transition.
Maturitas 14: 103-115
McMichael-Phillips DF. Harding C. Morton M. Roberts SA. Howell A.
Potten CS and Bundred NJ (1996) The effects ofsoy supplementation on
epithelial proliferation in the normal human breast. Breast CancerRes Treat
41: 263
Meyer JS 1977) Cell proliferation in normal human breast ducts. fibroadenomas.
and odher ductal hyperplasia measured by nuclear labelling- with tritiated
thymidine. Hwman Pathol 8: 67-81
Meyer JS and Connor RE (1982) Cell proliferation in fibrocystic disease and
posrnenopausal breast ducts measuredby thymidine labeling. Cancer50:
746-751
Moorhead T. Hannaford P and WarskNj M (1997) Prevalence and characteristics
associated with use ofhormone replacement therapy in Bn'tain. BrJ Obstet
Gvnaecol 104: 29-297
Pike MC. Spicer DV. Dahmoush L and Press MF ( 1993) Estrogens. progestogens.
nomal breast cell proliferation. and breast cancer risk. EpidemialRev 15:
17-35
Potten CS. Watson RJ. Williams GT. Tlickle S. Roberts SA. Harries M and How-ell A
(1988) The effect ofage and menstual cycle upon proliferative activity ofthe
normal human breast BrJ Cancer 58: 631-634
Preston-Martin S. Pike MC. Ross RKI Jones PA and Henderson BE (1990) Increased
cell division as a cause ofhuman cancer. CancerRes 50: 7415-7421
Soules. MR and Bremner WJ (1982) The menopause and climacteric. JAm
Geriatrics Soc 30: 547-561
Sullivan JM and Fowlkes MD (1996) Estrogens. menopause and coronar, heart
disease. Cardiol Clin 14: 105-116
Trichopoulos D. MacMahon B and Cole P ( 1972) Menopause and breast cancer nsk-
JNatl CancerInst48: 605-613
Walker KJ. Price-Thomas JM. Candlish W and Nicholson RI ( 1991) Influence ofthe
antioestoen tamoxifen on normal breast tissue. BrJ Cancer64: 764-768
Wellings SR Jensen HM and Marcum RG ( 1975) An atlas ofsubgrosspathology of
the human breastwith special reference to possible precancerous lesions. J Natl
CancerInst 55: 231-243
Whitehead MI. Townsend PI. Pnse-Davies J. Ryder TA and King RJ ( 1981 ) Effects
ofestrogens and progestins on the biochemistr- and morphology ofthe
postmenopausal endometriunm NEnglJMed305: 1599-1605
Whittaker PG. Morgan MRA. Dean PDG. Cameron EHD. Lind T (1980) Serum
equilin. oestrone and oestradiol levels in posrnenopausal womenreceiving
conjugated equine oestrogens (Premarin ). Lancet 8158: 14-15
Williams G. Anderson E. Howell A. Watson R. Coyne J. Roberts SA and Potten CS
(1991 ) Oral contraceptive (OCP) use increases proliferaion and decreases
oestrogen receptor content ofepithelial cells in the normal human breast.
IntJ Cancer48: 206-210
Yates RA. Dowsett M. Fisher GV. Selen A and Wyld PJ (1996) Arimidex (ZD1033
a selective. potent inhibitor ofaromatase in postmenopausal female volunteers.
BrJ Cancer 73: 543-548
0 Cancer Research Campaign 1998 British Journal ofCarcer(1998) 78(7), 945-949